세계의 인터페론 시장(2024-2028년)

The interferons market is forecasted to grow by USD 2.65 bn during 2023-2028, accelerating at a CAGR of 4.65% during the forecast period. The report on the interferons market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by increasing prevalence of viral infections, rising cases of autoimmune diseases, and advancements in biotechnology in developing recombinant interferons.

Technavio's interferons market is segmented as below:

By Type

• Interferon beta
• Interferon alfa
• Interferon gamma

By Indication

• Multiple sclerosis
• Hepatitis C
• Melanoma
• Leukemia
• Other indications

By Geographical Landscape

• North America
• Europe
• Asia
• Rest of World (ROW)

This study identifies the exploration of combination therapies involving interferons and other classes of drugs as one of the prime reasons driving the interferons market growth during the next few years. Also, growing emphasis on personalized medicine and increasing demand for biosimilars will lead to sizable demand in the market.

The report on the interferons market covers the following areas:

• Interferons market sizing
• Interferons market forecast
• Interferons market industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading interferons market vendors that include 3SBio Inc., Bayer AG, Biogen Inc., Biosidus SA, Bristol Myers Squibb Co., F. Hoffmann La Roche Ltd., Mega Labs SA, Merck KGaA, NANOGEN PHARMACEUTICAL BIOTECHNOLOGY JSC, Novartis AG, Pfizer Inc., PharmaEssentia Corp., Sanfer, Synairgen plc, and Zydus Lifesciences Ltd.. Also, the interferons market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.

Table of Contents

1 Executive Summary

• 1.1 Market overview

2 Market Landscape

• 2.1 Market ecosystem

3 Market Sizing

• 3.1 Market definition
• 3.2 Market segment analysis
• 3.3 Market size 2023
• 3.4 Market outlook: Forecast for 2023-2028

4 Historic Market Size

• 4.1 Global interferons market 2018 - 2022
• 4.2 Type Segment Analysis 2018 - 2022
• 4.3 Indication Segment Analysis 2018 - 2022
• 4.4 Geography Segment Analysis 2018 - 2022
• 4.5 Country Segment Analysis 2018 - 2022

5 Five Forces Analysis

• 5.1 Five forces summary
• 5.2 Bargaining power of buyers
• 5.3 Bargaining power of suppliers
• 5.4 Threat of new entrants
• 5.5 Threat of substitutes
• 5.6 Threat of rivalry
• 5.7 Market condition

6 Market Segmentation by Type

• 6.1 Market segments
• 6.2 Comparison by Type
• 6.3 Interferon beta - Market size and forecast 2023-2028
• 6.4 Interferon alfa - Market size and forecast 2023-2028
• 6.5 Interferon gamma - Market size and forecast 2023-2028
• 6.6 Market opportunity by Type

7 Market Segmentation by Indication

• 7.1 Market segments
• 7.2 Comparison by Indication
• 7.3 Multiple sclerosis - Market size and forecast 2023-2028
• 7.4 Hepatitis C - Market size and forecast 2023-2028
• 7.5 Melanoma - Market size and forecast 2023-2028
• 7.6 Leukemia - Market size and forecast 2023-2028
• 7.7 Other indications - Market size and forecast 2023-2028
• 7.8 Market opportunity by Indication

8 Customer Landscape

• 8.1 Customer landscape overview

9 Geographic Landscape

• 9.1 Geographic segmentation
• 9.2 Geographic comparison
• 9.3 North America - Market size and forecast 2023-2028
• 9.4 Europe - Market size and forecast 2023-2028
• 9.5 Asia - Market size and forecast 2023-2028
• 9.6 Rest of World (ROW) - Market size and forecast 2023-2028
• 9.7 US - Market size and forecast 2023-2028
• 9.8 UK - Market size and forecast 2023-2028
• 9.9 China - Market size and forecast 2023-2028
• 9.10 Germany - Market size and forecast 2023-2028
• 9.11 Japan - Market size and forecast 2023-2028
• 9.12 Market opportunity By Geographical Landscape

10 Drivers, Challenges, and Trends

• 10.1 Market drivers
• 10.2 Market challenges
• 10.3 Impact of drivers and challenges
• 10.4 Market trends

11 Vendor Landscape

• 11.1 Overview
• 11.2 Vendor landscape
• 11.3 Landscape disruption
• 11.4 Industry risks

12 Vendor Analysis

• 12.1 Vendors covered
• 12.2 Market positioning of vendors
• 12.3 3SBio Inc.
• 12.4 Bayer AG
• 12.5 Biogen Inc.
• 12.6 Biosidus SA
• 12.7 Bristol Myers Squibb Co.
• 12.8 F. Hoffmann La Roche Ltd.
• 12.9 Mega Labs SA
• 12.10 Merck KGaA
• 12.11 NANOGEN PHARMACEUTICAL BIOTECHNOLOGY JSC
• 12.12 Novartis AG
• 12.13 Pfizer Inc.
• 12.14 PharmaEssentia Corp.
• 12.15 Sanfer
• 12.16 Synairgen plc
• 12.17 Zydus Lifesciences Ltd.

13 Appendix

• 13.1 Scope of the report
• 13.2 Inclusions and exclusions checklist
• 13.3 Currency conversion rates for US$
• 13.4 Research methodology
• 13.5 List of abbreviations